Elevated plasma IGFBP2 levels correlate with malignancy risk in prostate cancer (71, 72) NSCLC studies link IGFBP2 overexpression to gefitinib resistance, reduced survival, and increased metastasis (73–75). Here, IGFBP2 is linked to Familial prostate cancer.